^
Association details:
Biomarker:No biomarker
Cancer:Renal Cell Carcinoma
Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
Inlyta (axitinib) (VEGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
09/22/2022
Excerpt:
INLYTA is a kinase inhibitor indicated...in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC)
Evidence Level:
Sensitive: A1 - Approval
Published date:
07/17/2015
Excerpt:
Keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults.
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426

Published date:
05/26/2022
Excerpt:
In this exploratory analysis, PFS2 was longer for patients randomized to pembro + axi compared to sunitinib.
DOI:
10.1200/JCO.2022.40.16_suppl.4513
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Published date:
10/23/2020
Excerpt:
With a median follow-up of 30·6 months (IQR 27·2–34·2), continued clinical benefit was observed with pembrolizumab plus axitinib over sunitinib in terms of overall survival (median not reached with pembrolizumab and axitinib vs 35·7 months [95% CI 33·3–not reached] with sunitinib); hazard ratio [HR] 0·68 [95% CI 0·55–0·85], p=0·0003) and progression-free survival (median 15·4 months [12·7–18·9] vs 11·1 months [9·1–12·5]; 0·71 [0·60–0·84], p<0·0001).
DOI:
10.1016/S1470-2045(20)30436-8
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Published date:
07/09/2020
Excerpt:
Median progression-free survival was 15.1 months in the pembrolizumab–axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab–axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001)....Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib.
DOI:
10.1056/NEJMoa1816714
Trial ID: